FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy

This publication has 12 references indexed in Scilit:

• Can positron emission tomography with [¹⁸F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
  British Journal of Haematology, 2001
• POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY
  Radiologic Clinics of North America, 2001
• Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([¹⁸F]FDG) After First-Line Chemotherapy in Non-Hodgkin’s Lymphoma: Is [¹⁸F]FDG-PET a Valid Alternative to Conventional Diagnostic Methods?
  Journal of Clinical Oncology, 2001
• 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas
  Annals of Oncology, 2000
• Spiral interpolation algorithm for multislice spiral CT. I. Theory
  IEEE Transactions on Medical Imaging, 2000
• Whole-Body Positron Emission Tomography Using18F-Fluorodeoxyglucose for Posttreatment Evaluation in Hodgkin’s Disease and Non-Hodgkin’s Lymphoma Has Higher Diagnostic and Prognostic Value Than Classical Computed Tomography Scan Imaging
  Blood, 1999
• Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography
  European Journal of Nuclear Medicine and Molecular Imaging, 1998
• Extranodal malignant lymphoma: detection with FDG PET versus CT.
  Radiology, 1998
• Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
  Radiology, 1997
• State of the art in emission tomography equipment.
  RadioGraphics, 1996